NCCN Guidelines® Insights - Hepatobiliary Cancers, Version 2.2019
The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s discussion and updated recommendations regarding systemic therapy for first-line and subsequent-line treatment of patients with hepatocellular carcinoma.
This activity is designed to meet the educational needs of physicians, nurses, pharmacists, and other healthcare professionals who manage patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate updates to the NCCN Guidelines for Hepatobiliary Cancers into the management of patients with hepatocellular carcinoma, with a focus on systemic therapy
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Hepatobiliary Cancers, with a focus on systemic therapy for hepatocellular carcinoma
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).
Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The NCCN staff listed below discloses no relevant financial relationships:
Kerrin M. Rosenthal, MA; Kimberly Callan, MS; Genevieve Emberger Hartzman, MA; Erin Hesler; Kristina M. Gregory, RN, MSN, OCN; Rashmi Kumar, PhD; Karen Kanefield; and Kathy Smith.
Individuals Who Provided Content Development and/or Authorship Assistance:
Al B. Benson III, MD, Panel Chair, has disclosed that he receives grant/research support from Acerta Pharma; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Infinity Pharmaceuticals, Inc.; MedImmune Inc.; Novartis Pharmaceuticals Corporation; and Taiho Parmaceuticals Co., Ltd. He also receives consulting fees/honoraria from Astellas Pharma US, Inc.; Bayer HealthCare; Bristol-Myers Squibb Company; Eli Lilly and Company; Exelixis Inc.; Genentech, Inc.; Merck & Co., Inc.; Purdue Pharma LP; and Taiho Parmaceuticals Co., Ltd.
Michael I. D’Angelica, MD, Panel Vice Chair, has disclosed that he has no relevant financial relationships.
Anne M. Covey, MD, Panel Member, has disclosed that she has equity interest/stock options in Amgen Inc., and is a scientific advisor for Accurate Medical
Renuka Iyer, MD, Panel Member, has disclosed that she receives grant/research support from Ipsen and Merck & Co., Inc., and receives consulting fees/honoraria Novartis Pharmaceuticals Corporation, Bayer HealthCare, Eisai, Inc., AAA Pharmaceutical Inc., and Lexicon Pharmaceuticals, Inc.
Alan P. Venook, MD, Panel Member, has disclosed that he serves as a scientific advisor for Bayer HealthCare, Bristol-Myers Squibb Company, Genentech, Inc., Merck & Co., Inc., and Taiho Pharmaceuticals Co., Ltd., and receives grant/research support from Genentech, Inc., and Merck & Co., Inc.
Lydia Hammond, MBA, Guidelines Layout Specialist, NCCN, has disclosed that she has no relevant financial relationships.
Susan D. Darlow, PhD, Oncology Scientist/Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.
To view all of the conﬂicts of interest for the panel, go to NCCN.org/disclosures/guidelinepanellisting.aspx.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-19-006-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until April 10, 2020. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation